Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes
To investigate the tolerability and safety of ASTX727 in Japanese subjects with lower-risk MDS.
Lower-risk Myelodysplastic
DRUG: ASTX727|DRUG: ASTX727|DRUG: ASTX727|DRUG: ASTX727|DRUG: ASTX727
Dose Limiting Toxicity, 28days
Area under the curve (AUC), pharmacokinetics parameter, Pre-dose, 15 min, 30 min, 60 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, 24 h after dosing|Maximum plasma concentration (Cmax), pharmacokinetics parameter, Pre-dose, 15 min, 30 min, 60 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, 24 h after dosing
To investigate the tolerability and safety of ASTX727 in Japanese subjects with lower-risk MDS.